Skip to main content
OpenTrials
Completed

NCT Number: NCT03627143

Decreasing Hospital Admissions From the ED for AAFF

Acute atrial fibrillation and flutter (AAFF) is characterized by rapid heart rates with onset less than seven days. It's the most common type of palpitation treated in the Emergency Department (ED). Some Canadian ED's will discharge 95% of AAFF patients whereas others admit up to 40%. With hospital and ED crowding, discharge is the most optimal, effective and safe strategy. Our aim is to improve the care and reduce the length of stay (LOS) of ED AAFF patients, while decreasing unnecessary hospitalizations. First, the investigators must understand the local barriers. In the previous study, the investigators conducted interviews of emergency physicians, cardiologists and AAFF patients. In Project 1b, the investigators created the CAEP ED AAFF Guidelines Checklist to assist physicians to manage AAFF more efficiently and safely. The Guidelines are comprised of two algorithms and four sets of checklists for ED assessment and management. They have been endorsed by CAEP and are published in CJEM.

The investigators are now planning Project 2 in which the investigators will conduct a cluster [group] randomized trial at 11 Canadian EDs and enroll 1,300 patients over thirteen months. The investigators are not randomizing individual patients or doctors; instead the investigators are randomizing the start date of individual hospitals. Our goal is to introduce the new Guidelines into these hospitals to improve the care of AAFF patients. The investigators hope to improve AAFF management, leading to a significant decrease in hospital admissions and ED LOS. Central to our plans will be engagement of our two patient partners. Our behaviorally optimized intervention will be developed using state-of-the-art implementation science approaches informed by the results of Project 1a. The investigators will also undertake within-project and end-of-project knowledge translation and implementation (KTI) strategies to facilitate scale up and roll out of our program to ED departments in small, medium, and large hospitals across Canada (future Project 3). Ultimately the investigators expect to improve ED practices and decrease AAFF admissions and LOS, without increasing visits.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Atrial Flutter Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr. Georges-L. - Dumont University Hospital, Moncton, New Brunswick, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

All eligible patients seen in the participating EDs during the study period will be included in the trial regardless of how they are managed.

Inclusion criteria

  • stable patients presenting with an episode of acute atrial fibrillation or flutter (AAFF) of at least 3 hours duration, where symptoms require ED management by rhythm or rate control.
  • patients with a history of prior episodes of AAFF, or those with previous presentations during the study periods.

Exclusion criteria

We will exclude patients who have any of the reasons listed below.

  • have permanent (chronic) AF
  • are deemed unstable and require immediate cardioversion: i) systolic blood pressure <90 mmHg; ii) rapid ventricular pre-excitation (Wolff-Parkinson-White syndrome); iii) acute coronary syndrome - ongoing severe chest pain and marked ST depression (>2mm) on ECG despite therapy; or iv) pulmonary edema - severe dyspnea requiring immediate IV diuretic, nitrates, or BIPAP;
  • the primary presentation was for another condition rather than arrhythmia
  • convert spontaneously to sinus rhythm prior to receiving physician-initiated therapy; or
  • die while in the ED from non-AAFF related causes.

Treatment and study plan

KTI activities

Other

The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.

  • Selection of one or more local physician champions from both the ED as well as the cardiology group;
  • Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;
  • Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;
  • Development of local action plan addressing local barriers to implementation;
  • Provision of the free Smartphone App to be developed for the guidelines;
  • Regular reminders provided by the local research staff;
  • Audit and feedback charts of site compliance

Primary outcomes

  1. length of stay in ED in minutes

    Time frame: a 100 minute reduction in ED length of stay (or a relative reduction of approximately 25%)

    Length of stay in ED in min. from time of arrival to time of discharge or admission.

Secondary outcomes

  1. Use of rhythm control in the ED

    Time frame: 13 months

    attempts at chemical or electrical cardioversion, as well as the success of these attempts (we believe these attempts facilitate ED discharge); compliance with the AAFF Guidelines will be assessed on criteria to be determined a priori by the investigators;

  2. Use of rate control and the final heart rate at disposition

    Time frame: 13 months

    compliance with the AAFF Guidelines will be assessed on criteria to be determined a priori by the investigators;

  3. Appropriate prescription of anticoagulants on discharge

    Time frame: 1 day

    anticoagulation prescription in compliance with the AAFF Guidelines

  4. Adverse events

    Time frame: 30 days from discharge from the ED

    measuring adverse events within 30 days of discharge from the emergency department

  5. Return ED visits and admission

    Time frame: 30 days

    for AAFF or related cardiovascular problems (stroke, CHF, AAFF, ACS or death), in the subsequent 30 days via a Health record reivew

Sponsors and collaborators

Lead sponsor

Ottawa Hospital Research Institute

Other

Collaborators

  • Cardiac Arrhythmia Network of Canada

Registry information

Official study title

Decreasing Hospital Admissions From the Emergency Department for Acute Atrial Fibrillation

Acronym: RAFF-3

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 13, 2018
Registry last updated
Jun 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.